Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanda Salutari

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
Endocrine|October 5, 2013
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imagingRosa Maria Paragliola, Francesco Torino, Paola Senes, et al.
Expert Opinion on Therapeutic Targets|February 8, 2024
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphereIlan Bruchim, Ilaria Capasso, Ariel Polonsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 30, 2018
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience"Anna Fagotti, Carmine Conte, Francesca Stollagli, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 11, 2014
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutationsPaola Concolino, Alessandra Costella, Angelo Minucci, et al.
Expert Review of Anticancer Therapy|June 11, 2024
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectivesElena Giudice, Vanda Salutari, Carolina Maria Sassu, et al.
Biology|September 28, 2021
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and PerspectivesAlessandra Giustozzi, Vanda Salutari, Elena Giudice, et al.
Cancers|April 3, 2021
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point InhibitorsCamilla Nero, Francesca Ciccarone, Antonella Pietragalla, et al.
Gynecologic Oncology|September 24, 2004
Cyclooxygenase-2 expression in borderline ovarian tumorsGabriella Ferrandina, Gian F Zannoni, Franco O Ranelletti, et al.
American Journal of Obstetrics and Gynecology|June 24, 2014
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancerMarco Petrillo, Gian Franco Zannoni, Lucia Tortorella, et al.
Case Reports in Oncology|November 30, 2020
Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the LiteratureGiuseppe Caruso, Lucia Musacchio, Giusi Santangelo, et al.
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
Endocrine|October 5, 2013
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imagingRosa Maria Paragliola, Francesco Torino, Paola Senes, et al.
Expert Opinion on Therapeutic Targets|February 8, 2024
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphereIlan Bruchim, Ilaria Capasso, Ariel Polonsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 30, 2018
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience"Anna Fagotti, Carmine Conte, Francesca Stollagli, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 11, 2014
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutationsPaola Concolino, Alessandra Costella, Angelo Minucci, et al.
Expert Review of Anticancer Therapy|June 11, 2024
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectivesElena Giudice, Vanda Salutari, Carolina Maria Sassu, et al.
Biology|September 28, 2021
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and PerspectivesAlessandra Giustozzi, Vanda Salutari, Elena Giudice, et al.
Cancers|April 3, 2021
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point InhibitorsCamilla Nero, Francesca Ciccarone, Antonella Pietragalla, et al.
Gynecologic Oncology|September 24, 2004
Cyclooxygenase-2 expression in borderline ovarian tumorsGabriella Ferrandina, Gian F Zannoni, Franco O Ranelletti, et al.
American Journal of Obstetrics and Gynecology|June 24, 2014
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancerMarco Petrillo, Gian Franco Zannoni, Lucia Tortorella, et al.
Case Reports in Oncology|November 30, 2020
Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the LiteratureGiuseppe Caruso, Lucia Musacchio, Giusi Santangelo, et al.
Pageof 11